MDT

86.83

+0.7%↑

121.59

+2.81%↑

VEEV

167.87

-0.17%↓

HQY

86.3

+2.51%↑

NEOG

9.64

+3.77%↑

MDT

86.83

+0.7%↑

121.59

+2.81%↑

VEEV

167.87

-0.17%↓

HQY

86.3

+2.51%↑

NEOG

9.64

+3.77%↑

MDT

86.83

+0.7%↑

121.59

+2.81%↑

VEEV

167.87

-0.17%↓

HQY

86.3

+2.51%↑

NEOG

9.64

+3.77%↑

MDT

86.83

+0.7%↑

121.59

+2.81%↑

VEEV

167.87

-0.17%↓

HQY

86.3

+2.51%↑

NEOG

9.64

+3.77%↑

MDT

86.83

+0.7%↑

121.59

+2.81%↑

VEEV

167.87

-0.17%↓

HQY

86.3

+2.51%↑

NEOG

9.64

+3.77%↑

Kodu・Aktsiate loetelu・Vaxart Inc

Vaxart Inc

Avatud

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

Max

Põhinäitajad
By Trading Economics
Sissetulek	63M 55M
Müük	32M 104M
P/E Sektori keskmine	10 63.808
Aktsiakasum	0.24
Kasumimarginaal	52.807
Töötajad	65
EBITDA	63M 58M

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	12. mai 2026

Turustatistika
By TradingEconomics
Turukapital	-23M 169M
Eelmine avamishind	0
Eelmine sulgemishind	0

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

0.4007 / 0.4252 Toetus ja vastupanu

Vaxart Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

16. apr 2026, 23:26 UTC

Kuumad aktsiad

Stocks to Watch: Netflix, Alcoa, Knight-Swift, NiSource

16. apr 2026, 20:41 UTC

Suurimad hinnamuutused turgudel

Netflix Shares Slide After 2Q Outlook Misses Wall Street's Expectations

16. apr 2026, 23:49 UTC

Market Talk

Amplitude's Pivot to Oil-Linked Supply Deal Catches Bull's Eye -- Market Talk

16. apr 2026, 23:45 UTC

Market Talk

Nikkei May Decline After Hitting Record High -- Market Talk

16. apr 2026, 23:33 UTC

Market Talk

Uudisväärsed sündmused

Gold Edges Higher on Hopes for U.S.-Iran Deal -- Market Talk

16. apr 2026, 22:51 UTC

Market Talk

Netflix Sees Signs That Podcasts May Boost Engagement -- Market Talk

16. apr 2026, 22:08 UTC

Tulu

Netflix Chair Reed Hastings to Leave Board in June -- 3rd Update

16. apr 2026, 22:06 UTC

Tulu

Lundin Mining: Earnings From Discontinued Ops in 1Q Expected to Be Positively Impacted by Unaudited Gain on Disposal of Eagle Mine, Totaling Approximately $4M >LUN.T

16. apr 2026, 22:06 UTC

Tulu

Lundin Mining: Pre-Announces Items Impacting 1Q Results

16. apr 2026, 22:06 UTC

Tulu

Lundin Mining: Items of Significant Impact in 1Q Expected to Include Unaudited Realized Losses on Derivative Contracts of Approximately $13M, Primarily Related to Gold Collar Contracts >LUN.T

16. apr 2026, 22:06 UTC

Tulu

Lundin Mining: Rev in 1Q Expected to Be Positively Impacted by Unaudited Provisional Pricing Adjustments on Prior-Period Concentrate Sales of Approximately $22M on Pre-Tax Basis >LUN.T

16. apr 2026, 22:06 UTC

Tulu

Lundin Mining: Adjustments Primarily Include Upward Adjustments in Relation to Prior-Period Metal Sales >LUN.T

16. apr 2026, 20:50 UTC

Market Talk

Tulu

Tech, Media & Telecom Roundup: Market Talk

16. apr 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

16. apr 2026, 20:50 UTC

Market Talk

Uudisväärsed sündmused

Basic Materials Roundup: Market Talk

16. apr 2026, 20:50 UTC

Market Talk

Tulu

Health Care Roundup: Market Talk

16. apr 2026, 20:49 UTC

Tulu

SpaceX Is Ready to Go Public. The Stock Market Is Its Rocket. -- Barrons.com

16. apr 2026, 20:43 UTC

Tulu

Update: Netflix Stock Falls on Weak Guidance. Founder Reed Hastings Is Leaving the Board. -- Barrons.com

16. apr 2026, 20:40 UTC

Market Talk

Tulu

Global Equities Roundup: Market Talk

16. apr 2026, 20:40 UTC

Market Talk

Tulu

Netflix Says Engagement Quality Hits New High -- Market Talk

16. apr 2026, 20:30 UTC

Kuumad aktsiad

Stocks to Watch: TSMC, Abbott Laboratories, Nvidia, Netflix -- WSJ

16. apr 2026, 20:25 UTC

Tulu

Netflix Stock Falls on Weak Guidance. Founder Reed Hastings Is Leaving the Board. -- Barrons.com

16. apr 2026, 20:23 UTC

Tulu

These Stocks Are Today's Movers: AMD, Intel, TSMC, Abbott, Hims, Corning, Schwab, Polaris, and More -- Barrons.com

16. apr 2026, 20:19 UTC

Tulu

Netflix Guidance Disappoints. The Stock Is Down. -- Barrons.com

16. apr 2026, 20:17 UTC

Tulu

Alcoa: Alumina Costs in the Aluminum Segment Are Expected to Be Favorable by Approximately $20M Sequentially >AA

16. apr 2026, 20:17 UTC

Tulu

Alcoa: Based on Higher LME and Midwest Premium Pricing and Expected Higher Shipments, Section 232 Tariff Costs on U.S. Imports of Aluminum From Canada Expected to Increase $35M Sequentially >AA

16. apr 2026, 20:16 UTC

Tulu

Alcoa: Expects 2026 Total Aluminum Segment Production and Shipments Ranging Between 2.4M and 2.6M Metric Tons, and Between 2.6M and 2.8M Metric Tons, Respectively >AA

16. apr 2026, 20:16 UTC

Tulu

Alcoa: Expects 2026 Total Aluminum Segment Production and Shipments to Remain Unchanged From Its Prior Projection >AA

16. apr 2026, 20:16 UTC

Tulu

Alcoa: Expects 2026 Total Alumina Segment Production and Shipments Ranging Between 9.7M to 9.9M Metric Tons, and Between 11.8M and 12.0M Metric Tons, Respectively >AA

16. apr 2026, 20:16 UTC

Tulu

Alcoa: Expects 2026 Total Alumina Segment Production and Shipments to Remain Unchanged From Prior Projection >AA

Võrdlus sarnastega

Hinnamuutus

Vaxart Inc Prognoos

Hinnangu Konsensus

By TipRanks

0 ratings

Osta

Hoia

Müü

Põhineb 0 analüütiku instrumendi Vaxart Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.4007 / 0.4252Toetus ja vastupanu

Recent bearish events outweigh bullish events.

There is one bearish event.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Vaxart Inc

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.